Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$47.37
-0.67-1.39%
At close: -
$47.37
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Disc Medicine Analyst Ratings and Price Targets | NASDAQ:IRON | Benzinga
Disc Medicine Inc has a consensus price target of $84 based on the ratings of 11 analysts. The high is $132 issued by Cantor Fitzgerald on March 18, 2025. The low is $36 issued by SVB Leerink on February 28, 2023. The 3 most-recent analyst ratings were released by BMO Capital, Cantor Fitzgerald, and Morgan Stanley on May 12, 2025, March 18, 2025, and March 7, 2025, respectively. With an average price target of $112.33 between BMO Capital, Cantor Fitzgerald, and Morgan Stanley, there's an implied 137.14% upside for Disc Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
Cantor Fitzgerald
Morgan Stanley
Scotiabank
Stifel
1calculated from analyst ratings
Analyst Ratings for Disc Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | 153.32% | BMO Capital | Evan Seigerman63% | $112 → $120 | Maintains | Outperform | Get Alert |
| 03/18/2025 | Buy Now | 178.66% | Cantor Fitzgerald | Kristen Kluska71% | $99 → $132 | Maintains | Overweight | Get Alert |
| 03/07/2025 | Buy Now | 79.44% | Morgan Stanley | Jeffrey Hung51% | → $85 | Assumes | → Overweight | Get Alert |
| 03/03/2025 | Buy Now | 58.33% | Scotiabank | Greg Harrison47% | $73 → $75 | Maintains | Sector Outperform | Get Alert |
| 01/24/2025 | Buy Now | 98.44% | Stifel | Benjamin Burnett43% | $90 → $94 | Maintains | Buy | Get Alert |
| 01/22/2025 | Buy Now | 54.11% | Scotiabank | Greg Harrison47% | $70 → $73 | Maintains | Sector Outperform | Get Alert |
| 01/21/2025 | Buy Now | 149.1% | HC Wainwright & Co. | Douglas Tsao51% | $118 → $118 | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 89.99% | Stifel | Benjamin Burnett43% | $79 → $90 | Maintains | Buy | Get Alert |
| 12/09/2024 | Buy Now | 149.1% | HC Wainwright & Co. | Douglas Tsao51% | $118 → $118 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2024 | Buy Now | 149.1% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $118 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 47.77% | Scotiabank | Greg Harrison47% | $62 → $70 | Maintains | Sector Outperform | Get Alert |
| 11/05/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 10/28/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 10/23/2024 | Buy Now | 87.88% | Jefferies | Roger Song34% | → $89 | Initiates | → Buy | Get Alert |
| 10/16/2024 | Buy Now | 30.88% | Scotiabank | Greg Harrison47% | → $62 | Initiates | → Sector Outperform | Get Alert |
| 10/15/2024 | Buy Now | 79.44% | Cantor Fitzgerald | Kristen Kluska71% | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 79.44% | Cantor Fitzgerald | Kristen Kluska71% | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 58.33% | Wells Fargo | Tiago Fauth45% | → $75 | Initiates | → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 20.33% | Wedbush | David Nierengarten61% | $57 → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 07/10/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 47.77% | BMO Capital | Evan Seigerman63% | $50 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 06/14/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 79.44% | Cantor Fitzgerald | Kristen Kluska71% | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 05/15/2024 | Buy Now | 79.44% | Cantor Fitzgerald | Kristen Kluska71% | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | -9.23% | Raymond James | Danielle Brill44% | $40 → $43 | Maintains | Outperform | Get Alert |
| 04/08/2024 | Buy Now | 54.11% | Stifel | Benjamin Burnett43% | $71 → $73 | Maintains | Buy | Get Alert |
| 04/02/2024 | Buy Now | -15.56% | Morgan Stanley | Jeffrey Hung51% | $75 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/02/2024 | Buy Now | 5.55% | BMO Capital | Evan Seigerman63% | $80 → $50 | Maintains | Outperform | Get Alert |
| 04/02/2024 | Buy Now | 49.88% | Stifel | Benjamin Burnett43% | $104 → $71 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | Buy Now | -15.56% | Raymond James | Danielle Brill44% | $75 → $40 | Downgrade | Strong Buy → Outperform | Get Alert |
| 03/22/2024 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $70 → $70 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 119.55% | Stifel | Benjamin Burnett43% | $76 → $104 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 68.88% | BMO Capital | Evan Seigerman63% | $70 → $80 | Maintains | Outperform | Get Alert |
| 12/20/2023 | Buy Now | 79.44% | Cantor Fitzgerald | Kristen Kluska71% | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | Buy Now | 37.22% | Morgan Stanley | Jeffrey Hung51% | $56 → $65 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/14/2023 | Buy Now | 47.77% | HC Wainwright & Co. | Douglas Tsao51% | $66 → $70 | Maintains | Buy | Get Alert |
| 06/12/2023 | Buy Now | 18.22% | Morgan Stanley | Jeffrey Hung51% | $37 → $56 | Maintains | Overweight | Get Alert |
| 06/12/2023 | Buy Now | 47.77% | BMO Capital | Evan Seigerman63% | $40 → $70 | Maintains | Outperform | Get Alert |
| 06/12/2023 | Buy Now | 58.33% | Raymond James | Danielle Brill44% | $50 → $75 | Upgrade | Outperform → Strong Buy | Get Alert |
| 06/09/2023 | Buy Now | 5.55% | Stifel | Benjamin Burnett43% | $40 → $50 | Maintains | Buy | Get Alert |
| 06/09/2023 | Buy Now | 37.22% | Cantor Fitzgerald | Kristen Kluska71% | $45 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/09/2023 | Buy Now | 58.33% | Raymond James | Danielle Brill44% | $50 → $75 | Upgrade | Outperform → Strong Buy | Get Alert |
| 06/09/2023 | Buy Now | 39.33% | HC Wainwright & Co. | Douglas Tsao51% | $55 → $66 | Reiterates | → Buy | Get Alert |
| 06/07/2023 | Buy Now | 16.11% | HC Wainwright & Co. | Douglas Tsao51% | → $55 | Initiates | → Buy | Get Alert |
| 05/17/2023 | Buy Now | 5.55% | Raymond James | Danielle Brill44% | → $50 | Initiates | → Outperform | Get Alert |
| 04/28/2023 | Buy Now | -5% | Cantor Fitzgerald | Kristen Kluska71% | → $45 | Initiates | → Overweight | Get Alert |
| 04/26/2023 | Buy Now | -24% | Wedbush | David Nierengarten61% | $32 → $36 | Maintains | Outperform | Get Alert |
| 04/21/2023 | Buy Now | -21.89% | Morgan Stanley | Jeffrey Hung51% | → $37 | Reiterates | → Overweight | Get Alert |
| 04/21/2023 | Buy Now | -21.89% | Stifel | Benjamin Burnett43% | → $37 | Initiates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | -21.89% | Morgan Stanley | Jeffrey Hung51% | → $37 | Initiates | → Overweight | Get Alert |
| 03/23/2023 | Buy Now | -15.56% | BMO Capital | Evan Seigerman63% | → $40 | Initiates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | -24% | SVB Leerink | Thomas Smith33% | → $36 | Initiates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | -36.67% | Wedbush | David Nierengarten61% | → $30 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Disc Medicine (IRON) stock?
The latest price target for Disc Medicine (NASDAQ:IRON) was reported by BMO Capital on May 12, 2025. The analyst firm set a price target for $120.00 expecting IRON to rise to within 12 months (a possible 153.32% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Disc Medicine (IRON)?
The latest analyst rating for Disc Medicine (NASDAQ:IRON) was provided by BMO Capital, and Disc Medicine maintained their outperform rating.
When was the last upgrade for Disc Medicine (IRON)?
The last upgrade for Disc Medicine Inc happened on June 12, 2023 when Raymond James raised their price target to $75. Raymond James previously had an outperform for Disc Medicine Inc.
When was the last downgrade for Disc Medicine (IRON)?
The last downgrade for Disc Medicine Inc happened on April 1, 2024 when Raymond James changed their price target from $75 to $40 for Disc Medicine Inc.
When is the next analyst rating going to be posted or updated for Disc Medicine (IRON)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Disc Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Disc Medicine was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating Disc Medicine (IRON) correct?
While ratings are subjective and will change, the latest Disc Medicine (IRON) rating was a maintained with a price target of $112.00 to $120.00. The current price Disc Medicine (IRON) is trading at is $47.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
